Patrick Texereau

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Pascal Hammel, Mohamed Hebbar et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +14

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Florence Castan, Anthony Lopez et al. · JAMA Oncology · 2022 · 324 citations · Full text

Medicine, Oncology, Surgery +14

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 164 citations · Full text

Medicine, Infectious Diseases, Oncology +14

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial

Michel Ducreux, David Malka, Jean Mendiboure et al. · The Lancet Oncology · 2011 · 155 citations

Medicine, Oncology, Chemotherapy +5

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

Anthony Dohan, B. Gallix, Boris Guiu et al. · Gut · 2019 · 138 citations

Medicine, Oncology, Radiology +17